|Articles|March 15, 2004

EC approves bimatoprost as first-line therapy

London-The European Commission (EC) has approved Allergan Inc.'s bimatoprost ophthalmic solution 0.03% (Lumigan) as a first-line therapy to reduce IOP in chronic open-angle glaucoma and ocular hypertension.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Latest CME